|
|
Legal status
Patent in force
| (51) | INT.CL. | C07D 487/04 | (2006.01) |
| A61P 35/00 | (2006.01) | ||
| A61K 31/53 | (2006.01) |
| (11) | Number of the document | 3953357 |
| (13) | Kind of document | T |
| (96) | European patent application number | 20721083.2 |
| Date of filing the European patent application | 2020-04-08 | |
| (97) | Date of publication of the European application | 2022-02-16 |
| (45) | Date of publication and mention of the grant of the patent | 2024-04-17 |
| (46) | Date of publication of the claims translation | 2024-07-25 |
| (86) | Number | PCT/US2020/027177 |
| Date | 2020-04-08 |
| (87) | Number | WO 2020/210293 |
| Date | 2020-10-15 |
| (30) | Number | Date | Country code |
| 201962833529 P | 2019-04-12 | US | |
| 201962911016 P | 2019-10-04 | US | |
| 201962930240 P | 2019-11-04 | US |
| (72) |
KIM, Joseph, L. , US
DINEEN, Thomas, A. , US
GUZI, Timothy , US
|
| (73) |
Blueprint Medicines Corporation ,
45 Sidney Street, Cambridge, MA 02139,
US
|
| (74) |
Vitalija BANAITIENÄ–,
UAB TARPINÄ–, A.P.Kavoliuko g. 24-152, LT-04328 Vilnius,
LT
|
| (54) | Pirolotriazino dariniai, skirti KIT ir PDGFRA sukeltoms ligoms gydyti |
| PYRROLOTRIAZINE DERIVATIVES FOR TREATING KIT- AND PDGFRA-MEDIATED DISEASES |
| Payment date | Validity (years) | Amount | |
| 2026-03-03 | 7 | 162.00 EUR |
| 2027-04-08 |